Sarepta (SRPT) COO Estepan reports PSU vesting and tax share withholding

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported equity award activity tied to prior grants. On March 1, 2026, 8,125 Performance Stock Units earned under a March 1, 2024 award were converted into 8,125 shares of common stock as they vested based on milestone achievement.

To cover tax withholding on the vesting of this PSU award and related restricted stock units, the company withheld a total of 4,176 shares of common stock on March 2, 2026, valued at $16.20 per share, as tax-withholding dispositions. After these non‑market transactions, Estepan directly owned 204,699 common shares.

Insider Trade Summary

8,125 shares exercised/converted

Mixed 4 txns

Insider Estepan Ian Michael

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	3,301	$16.20	$53K
Tax Withholding	Common Stock	875	$16.20	$14K
Exercise	Performance Stock Units	8,125	$0.00	--
Exercise	Common Stock	8,125	$0.00	--

Holdings After Transaction: Common Stock — 205,574 shares (Direct); Performance Stock Units — 0 shares (Direct)

Footnotes (1)

1. Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of a PSU award granted on March 1, 2024. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Estepan Ian Michael

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		M		8,125	A	(1)	208,875	D
Common Stock	03/02/2026		F(2)		3,301	D	$16.2	205,574	D
Common Stock	03/02/2026		F(3)		875	D	$16.2	204,699	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	03/01/2026		M			8,125	(1)	(1)	Common Stock	8,125	$0	0	D

Explanation of Responses:

1. Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.

2. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of a PSU award granted on March 1, 2024.

3. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Ian Michael Estepan	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Sarepta (SRPT) COO Ian Michael Estepan report?

Ian Michael Estepan reported vesting-related equity activity, not open-market trades. 8,125 Performance Stock Units granted March 1, 2024 vested into common stock, and the company withheld 4,176 shares to satisfy tax obligations tied to these PSU and restricted stock unit vestings.

How many Sarepta (SRPT) shares did the COO receive from PSU vesting?

The COO received 8,125 shares of Sarepta common stock from the conversion of previously earned Performance Stock Units. These PSUs were granted March 1, 2024 and vested March 1, 2026 after the Compensation Committee determined the company met the prescribed performance milestones.

Were Sarepta (SRPT) shares actually sold on the market in this Form 4?

The filing shows no open-market sales. Instead, 3,301 and 875 shares of Sarepta common stock were withheld by the company at $16.20 per share to cover tax withholding obligations related to vesting PSUs and restricted stock units from the March 1, 2024 awards.

How many Sarepta (SRPT) shares does the COO own after these transactions?

After all vesting conversions and tax-withholding dispositions, Ian Michael Estepan directly holds 204,699 shares of Sarepta common stock. This figure reflects the 8,125 shares issued from vested PSUs minus the 4,176 shares withheld to satisfy associated tax obligations.

What do the footnotes in the Sarepta (SRPT) Form 4 explain about these awards?

The footnotes explain that 8,125 shares came from a Performance Stock Unit award granted March 1, 2024, earned based on milestone achievement and vesting March 1, 2026. They also clarify that certain shares were withheld solely to satisfy tax obligations from PSU and restricted stock unit vesting.